

The following table shows the financial results for Merck & Co., Inc. and subsidiaries for the quarter ended March 31, 2008 compared with the corresponding period of the prior year.

Merck & Co., Inc.
Consolidated Results
(in Millions Except Earnings per Common Share)
Quarter Ended March 31
(Unaudited)

	<u>2008</u>	<u>2007</u>	<u>% Change</u>
Sales	\$5,822.1	\$5,769.4	1%
Costs, Expenses and Other			
Materials and production ⁽¹⁾	1,238.1	1,525.8	(19)
Marketing and administrative ⁽²⁾	1,854.4	1,802.0	3
Research and development	1,078.3	1,030.0	5
Restructuring costs ⁽³⁾	69.7	65.8	6
Equity income from affiliates	(652.1)	(652.6)	
Other (income) expense, net ⁽⁴⁾	(2,177.3)	(256.0)	*
Income Before Taxes	4,411.0	2,254.4	96
Taxes on Income ⁽⁵⁾	1,108.4	550.1	
Net Income	\$3,302.6	\$1,704.3	94
Average Shares Outstanding			
Assuming Dilution	2,174.7	2,180.0	
Earnings per Common Share			
Assuming Dilution	\$1.52	\$0.78	95

* > 100%

(1) Includes restructuring costs of \$14.9 million in the first quarter of 2008 and \$118.1 million in the first quarter of 2007 primarily related to accelerated depreciation and asset impairment costs associated with Merck's global restructuring program announced in November 2005.

(2) Includes the impact of reserving an additional \$40 million in the first quarter of 2008 solely for future legal defense costs for FOSAMAX litigation.

(3) Restructuring costs represent separation and other related costs, as well as gains on sales of facilities and related assets in the first quarter of 2008, associated with the global restructuring program.

(4) Other (income) expense, net in the first quarter 2008 reflects a \$2.2 billion gain related to a distribution from AstraZeneca LP, a \$300 million expense for a contribution to The Merck Company Foundation, a \$249 million gain on the Company's remaining worldwide rights to AGGRASTAT, and a \$55 million charge in connection with the anticipated resolution of an investigation into whether the Company violated state consumer protection laws with respect to the sales and marketing of VIOXX. Other (income) expense, net in the first quarter of 2007 primarily reflects the favorable impact of gains on sales of assets and product divestitures.

(5) The effective tax rate of 25.1% in the first quarter of 2008 reflects the impacts of the gain on distribution from AstraZeneca LP and restructuring charges. In addition, the tax rate reflects a first-quarter benefit relating to the realization of foreign tax credits.